Loading clinical trials...

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients? | Clinical Trials | Clareo Health

COMPLETEDNA

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients

NCT05359341•Sadat City University

View on ClinicalTrials.gov

Summary

Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.

Eligibility

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type 2 male/female diabetic patients
•Age 20-70 years
•A1C less than 10.5%

Exclusion Criteria

•Type 1 diabetes; HbA1c \> 10.5%
•Pregnancy
•Chronic liver disease
•Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.
•High bilirubin
•Albumin \< 3.5 g/dl
•INR \>1-2 Diabetic ketoacidosis
•Urinary tract infection (UTI)
•Pancreatitis \< 6 months prior to enrolment
•Renal impairment (creatinine clearance ≤50 ml/min)
+2 more criteria

Locations (1)

University of Sadat City

El Sadat, Egypt

Key Dates

Start Date

September 20, 2020

Primary Completion Date

September 20, 2021

Completion Date

January 10, 2022

Last Updated

May 3, 2022

Enrollment

175

ACTUAL participants

Conditions

Diabete Type 2

Interventions

Sitagliptin 50 mg

DRUG

Empagliflozin 12.5 MG

DRUG

Sitagliptin 50 mg + Empagliflozin 12.5 MG

DRUG

Empagliflozin 12.5 MG + Sitagliptin 50 mg

DRUG

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT05268237

Diabete Type 2

View study

RECRUITING

SGLT-2 Inhibitors in the Treatment of Ascites

NCT05999773

Ascites HepaticCirrhosis, Liver+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 3, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Inclusion Criteria

Exclusion Criteria

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

SGLT-2 Inhibitors in the Treatment of Ascites

Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy

Monitoring of the Sympathetic/Vagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)

Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction